Swinburn C R, Wakefield J M, Jones P W
Thorax. 1985 Aug;40(8):581-6. doi: 10.1136/thx.40.8.581.
Seventeen patients (six men and 11 women, mean age 66 years) with severe chronic obstructive lung disease (mean FEV1 0.8 (SD 0.3)1) performed three different types of exercise test on four occasions within one week. Three daily doses of placebo tablets were given between the third and fourth attempt at each test. The tests were the 12 minute walking test, a fixed rate and height paced step test, and a cycle ergometer test in which the work rate was increased by 10 watts each minute. Performance increased significantly (p less than 0.01) between the first and fourth attempts in each type of test (12 min walking distance 16% (SD 20%); steps climbed 96% (74%); duration of cycling 29% (41%]. There was a trend for the increase in performance between successive attempts to become progressively smaller but this was not significant. No effect of placebo on exercise performance was detected. The greatest intersubject range of performance was seen in the step test (14-126 steps) and the least in the walking test (438-1014 m). Significant correlations (p less than 0.01) were observed between performance in all three types of exercise test, but the correlations found between the results of the various tests of exercise performance and the FEV1 and the FVC were either weak (p less than 0.05) or non-significant. Ventilation (VE) and oxygen consumption (VO2) were subsequently measured and compared in eight patients during all three types of exercise test. Both the VE and the VO2 that were achieved in the step test were significantly greater than in either the cycle or the walking test. No patient was able to reach and sustain steady state values of VE and VO2 in the step test, whereas a steady state for both VE and VO2 was reached and sustained by all eight patients in the walking test. It is suggested that at least three practice attempts at any exercise test should be made before the introduction of either placebo or specific pharmacological treatment and that even then it may be necessary to allow for the effects of further repeated testing in the assessment of the results of treatment.
17例重度慢性阻塞性肺疾病患者(6例男性,11例女性,平均年龄66岁,平均第一秒用力呼气容积(FEV1)为0.8(标准差0.3)升)在一周内分四次进行了三种不同类型的运动试验。每次试验的第三次和第四次尝试之间给予每日三次剂量的安慰剂片。试验包括12分钟步行试验、固定速率和高度的阶梯试验以及自行车测力计试验,其中自行车测力计试验的工作负荷每分钟增加10瓦。在每种类型的试验中,第一次和第四次尝试之间的表现显著提高(p<0.01)(12分钟步行距离增加16%(标准差20%);爬阶梯数增加96%(74%);骑行持续时间增加29%(41%))。连续尝试之间表现增加的趋势逐渐变小,但这并不显著。未检测到安慰剂对运动表现有影响。在阶梯试验中观察到受试者之间最大的表现范围(14 - 126级阶梯),而在步行试验中最小(438 - 1014米)。在所有三种类型的运动试验表现之间观察到显著相关性(p<0.01),但运动表现的各种试验结果与FEV1和用力肺活量(FVC)之间发现的相关性要么较弱(p<0.05),要么不显著。随后在8例患者的所有三种类型运动试验期间测量并比较了通气量(VE)和耗氧量(VO2)。阶梯试验中达到的VE和VO2均显著高于自行车试验或步行试验。在阶梯试验中没有患者能够达到并维持VE和VO2的稳定状态值,而在步行试验中所有8例患者均达到并维持了VE和VO2的稳定状态。建议在引入安慰剂或特定药物治疗之前,对任何运动试验至少进行三次练习尝试,即便如此,在评估治疗结果时可能仍有必要考虑进一步重复测试的影响。